Endometriosis Treatment Market Size & Share 2026-2035

Endometriosis Treatment Market Size

The global endometriosis treatment market was valued at USD 1.9 billion in 2025 to USD 6.5 billion by 2035, expanding at a 13.4% CAGR from 2026 to 2035. Demand is rooted in a substantial diagnosed and underserved patient population: endometriosis affects an estimated 190 million women of reproductive age globally, or approximately 10% of that population ^{[1]World Health Organization - Endometriosis, 2023 - who.int}.

Treatment demand is increasingly shaped by the shift from symptom control through conventional analgesics and hormonal products toward oral gonadotropin-releasing hormone (GnRH) antagonists and combination therapies designed to control pain while managing hypoestrogenic effects. AbbVie's Orilissa was approved in the United States for moderate-to-severe endometriosis-associated pain in 2018 ^{[2]U.S. Food and Drug Administration - NDA 210450 approval letter for Orilissa, July 23, 2018 - fda.gov}, while Pfizer and Myovant's once-daily Myfembree received U.S. approval for the same indication in 2022. These products have expanded the commercial importance of long-duration, oral, prescription-based management.

The addressable market is not defined solely by prevalence. Delayed recognition, variable lesion presentation, fertility concerns, reimbursement conditions, and tolerability constraints influence whether a patient enters pharmacological treatment, remains on therapy, or moves to surgery. Consequently, diagnostic progress and disease awareness can increase treatment initiation, whereas affordability and product access determine whether that clinical demand converts into sustained pharmaceutical use.

The market's principal tension is that the largest clinical need is not necessarily the most commercially accessible. Countries with stronger specialist referral networks and reimbursement systems can convert diagnosis into recurring therapy, while lower-resource settings may continue to rely on lower-cost symptom management or delayed intervention. Manufacturers that pair differentiated efficacy with access programs, country-specific registration, and practical treatment-monitoring support are better positioned to translate awareness into durable demand.

Key Drivers

Rising prevalence and awareness of endometriosis

Endometriosis affects approximately 190 million women of reproductive age worldwide. In the United States, the condition may affect more than 11% of women aged 15–44, and more than 6.5 million women are estimated to have endometriosis. This scale increases the importance of earlier symptom recognition, especially where chronic pelvic pain, dysmenorrhea, and infertility have historically been normalized or treated without a disease-specific pathway.

Awareness activity can influence the market by shortening the distance between symptoms, specialist consultation, diagnosis, and therapy. The Endometriosis Association has distributed 2,577 Teen Outreach educational packages across 34 U.S. states ^{[3]Endometriosis Association - Education, current - endometriosisassn.org}. While education programs do not directly create prescriptions, they can improve symptom literacy among patients and caregivers, supporting earlier clinical engagement and expanding the pool eligible for medical management.

Advancements in diagnostic techniques

Improving diagnostic pathways can increase treatment demand by identifying disease earlier and distinguishing endometriosis from other causes of pelvic pain. Less invasive assessment approaches and more targeted referral practices have particular commercial relevance because medical treatment is often initiated before, alongside, or instead of surgical intervention. A more confident diagnosis also supports sustained use of disease-directed hormonal therapy rather than repeated short-term analgesic treatment.

Diagnostic progress has the greatest commercial effect where it is connected to gynecology capacity, imaging access, and clear referral pathways. Earlier identification can increase the duration over which a patient receives pharmacological management, but it also raises the need for products with tolerability profiles suitable for continued use. This favors therapies that combine pain control with more manageable estrogen-suppression effects.

Increased government funding and initiatives

Government attention to women's health is strengthening the institutional infrastructure around endometriosis care. In February 2025, the Australian Government announced AUD 573.3 million for women's health measures, including endometriosis and pelvic pain clinics ^{[4]Australian Government, Department of Health and Aged Care - Australian Government strengthening Medicare with over $500 million for women's health, February 9, 2025 - health.gov.au}. Dedicated clinics can improve referral quality, concentrate specialist expertise, and create clearer channels for diagnosis and treatment selection.

Public investment is most consequential when it improves care delivery rather than operating as awareness spending alone. Expanded specialist services can increase the number of patients reaching appropriate hormonal treatment, while also exposing access gaps for medicines requiring ongoing monitoring or reimbursement approval. Suppliers therefore benefit when market-access planning is coordinated with public health initiatives and local clinical pathways.

Key Restraints

High cost of advanced treatments

Advanced GnRH antagonist regimens, add-back combinations, specialist consultations, diagnostic imaging, and minimally invasive procedures can create a cumulative affordability barrier. This matters most in markets where treatment costs are borne substantially by patients or where reimbursement is limited to narrow eligibility criteria. The barrier can reduce treatment persistence even after diagnosis, shifting demand toward lower-cost oral contraceptives, NSAIDs, or intermittent symptom management.

Cost pressure also changes competitive behavior. Innovators must demonstrate a credible clinical and economic rationale for premium therapies, while generic and established hormonal products retain relevance where reimbursement is restrictive. The restraint is especially acute in emerging markets, where growing awareness can increase demand without ensuring that patients can afford specialist-led, long-term treatment.

Cost remains the counterweight to this demand-building cycle. A broader diagnosed population may enlarge the clinical market without proportionally enlarging the premium-drug market if payer policies and household affordability remain unchanged. The resulting opportunity favors portfolio strategies that span established hormonal products, differentiated oral GnRH therapies, and locally viable distribution arrangements rather than relying on a single high-cost treatment model.

Endometriosis Treatment Market Segment Analysis

By Disease Type

Superficial peritoneal endometriosis accounted for 48.30% of the market and is projected to grow at a 13.09% CAGR. It is the most common subtype and has been reported in up to 80% of women with endometriosis ^{[5]NIH PubMed Central - Superficial endometriosis prevalence, 2025 - nih.gov}. Its large share reflects the broad clinical applicability of hormonal therapy and pain management across a substantial patient population.

Ovarian endometriomas represented 28.10% of the market and are forecast to expand at a 13.50% CAGR. Treatment decisions in this segment are shaped by ovarian involvement, fertility considerations, recurrence risk, and the balance between medical management and surgery. Deep infiltrating endometriosis held a 19.20% share and is expected to record the highest disease-type CAGR at 14.02%, reflecting the intensive symptom burden and specialist management often associated with deeper lesions. Other disease types accounted for 4.40% of the market and are projected to grow at 12.84%.

By Treatment Type

Hormone therapy generated 79.40% of market revenue and is forecast to grow at a 13.78% CAGR. Its dominance reflects the central role of estrogen suppression or modulation in managing endometriosis-associated pain. The category includes oral contraceptives, progestins, GnRH agonists, GnRH antagonists, and combination regimens that incorporate add-back therapy.

Pain medication accounted for 20.60% of the market and is projected to expand at an 11.63% CAGR. NSAIDs and other analgesic approaches remain important for symptom relief, particularly when patients are awaiting diagnosis, cannot tolerate hormonal options, or use pain management alongside disease-directed therapy. Their lower growth rate indicates that analgesia alone is less aligned with the market's move toward longer-term hormonal disease management.

By Drug Class

GnRH products held a 49.30% share and are expected to grow at a 13.84% CAGR. The class includes established injectable agonists and newer oral antagonists. The latter have broadened options for patients requiring targeted estrogen suppression, while combination products seek to address the consequences of prolonged hypoestrogenism.

Oral contraceptives represented 26.50% of revenue and are forecast to grow at a 12.84% CAGR. Their established use, familiarity among clinicians, and accessibility retain commercial significance, although their role can be constrained when pain remains inadequately controlled. NSAIDs accounted for 15.40% of the market and are projected to grow at 12.64%, while other drug classes held 8.80% and are expected to expand at 13.58%.

By Route of Administration

Oral therapies accounted for 64.40% of the market and are anticipated to grow at a 13.27% CAGR. Daily oral administration aligns with the treatment formats of oral contraceptives, progestins, NSAIDs, and newer GnRH antagonist combinations. Convenience supports outpatient management and can reduce dependence on administration visits.

Injectables held a 32.70% share and are projected to grow at a 13.72% CAGR. Their position remains supported by established GnRH agonist use and specialist-led care pathways. Other routes of administration represented 2.90% of market revenue and are forecast to expand at 11.66%.

By Distribution Channel

Hospital pharmacies accounted for 52.20% of the market and are expected to grow at a 13.04% CAGR. Their leading position reflects the role of hospital-based gynecology, specialist consultations, and monitored treatment initiation in endometriosis management. Retail pharmacies held a 37.10% share and are projected to grow at 13.50%, supported by recurring dispensing for oral therapies.

Online pharmacies represented 10.70% of the market and are forecast to grow at the fastest rate, 14.54%. Their growth depends on prescription fulfillment rules, digital-health adoption, and patient comfort with recurring delivery. The channel is likely to be most effective for established oral regimens rather than complex therapies requiring close initiation or monitoring.

Deep infiltrating disease has the fastest disease-type growth despite its smaller base, indicating that higher-acuity patients can contribute disproportionately to specialist and advanced-treatment demand. At the same time, superficial peritoneal disease remains the largest commercial segment because of its broad prevalence. Suppliers need to manage both realities: scalable therapy access for large patient populations and clinically differentiated approaches for complex disease presentations.

Endometriosis Treatment Market Regional Analysis

North America

North America held a 42.60% global market share in 2024 and is projected to grow at a 13.50% CAGR, increasing from USD 714.75 million in 2024 to USD 2.79 billion by 2035. The U.S. represented 90.70% of the regional market in 2024 and is forecast to expand at 13.33%, while Canada accounted for 9.30% and is expected to grow at 14.95%.

The region's scale is supported by specialist care capacity, higher diagnosis visibility, and availability of branded GnRH therapies. More than 11% of American women aged 15–44 may be affected by endometriosis. North American disease-type demand is led by superficial peritoneal endometriosis at 47.85%, followed by ovarian endometriomas at 28.27%, deep infiltrating endometriosis at 19.55%, and other disease types at 4.33%. Hormone therapy accounts for 79.40% of regional treatment revenue, while GnRH products hold 49.30% of drug-class demand.

Europe

Europe accounted for 29.60% of global revenue in 2024 and is projected to expand at a 13.10% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands form the region's principal treatment markets. European demand is supported by established gynecological care systems, broad use of hormonal management, and continued regulatory activity around oral combination therapies.

Germany provides an indication of the region's treatment burden: approximately 32,000 hospital stays with a primary diagnosis of endometriosis were recorded in 2022, equivalent to 0.8 cases per 1,000 persons ^{[6]Deutsches Ärzteblatt International - Endometriosis in Germany: hospital statistics and healthcare data, September 20, 2024 - aerzteblatt.de}. Market development varies across national reimbursement systems, making local pricing and access strategy important for differentiated GnRH products.

Asia Pacific

Asia Pacific held a 21.90% global share in 2024 and is forecast to record the fastest regional CAGR at 13.89%. Japan, China, India, Australia, and South Korea are the key country markets. India alone is estimated to have approximately 42 million women affected by endometriosis ^{[7]NIH PubMed Central - Endometriosis in India, 2025 - nih.gov}. This large potential patient base creates a significant opportunity, but diagnosis, affordability, and specialist availability vary materially among countries.

The region's need for accessible reproductive-health services remains substantial. UNFPA estimates that 140 million women in Asia and the Pacific have an unmet need for family planning. Although this measure is not an endometriosis prevalence indicator, it illustrates the broader reproductive-health access constraints that can affect consultation, treatment continuity, and uptake of prescription therapies. Australia's expanded public focus on endometriosis and pelvic pain clinics may offer a more structured pathway for earlier diagnosis and specialist care.

Latin America

Latin America accounted for 3.32% of the global market in 2024 and is anticipated to grow at a 12.65% CAGR. Brazil, Mexico, and Argentina are the principal country markets. Growth is supported by increasing awareness among clinicians and patients, but uneven access to gynecologists, diagnostic imaging, and reimbursement constrains adoption of premium therapies.

Commercial expansion in the region will depend less on global product availability than on local affordability and distribution. Companies with practical pricing structures, retail pharmacy reach, and medical education capabilities are more likely to address the gap between rising awareness and consistent treatment use.

Middle East & Africa

Middle East & Africa represented 2.58% of global market revenue in 2024 and is projected to grow at a 10.56% CAGR. South Africa, Saudi Arabia, and the UAE are the key markets. The region has a smaller commercial base because specialized diagnostic pathways and dedicated endometriosis services remain limited in many countries.

Growth will be determined by the pace at which reproductive-health stigma, referral barriers, and diagnostic infrastructure are addressed. Higher-income Gulf markets may support branded treatment adoption through private and specialized care, while broader regional expansion will require greater affordability and integration of endometriosis management into routine gynecological services.

Asia Pacific presents the strongest growth profile because its 13.89% CAGR combines a large potential patient base with improving awareness and policy attention. Yet the region cannot be approached as a single access market: Australia's clinic-based public investment, Japan's established pharmaceutical environment, India's large patient population, and China's evolving specialist capacity require different pricing, registration, and distribution models. Latin America and Middle East & Africa offer longer-term expansion potential, but affordability and diagnostic infrastructure remain more decisive than product differentiation alone.

Endometriosis Treatment Market Share & Competitive Landscape

AbbVie participates through Orilissa, an elagolix product approved by the U.S. Food and Drug Administration for the management of moderate-to-severe endometriosis-associated pain. The product established an oral GnRH antagonist option in a category historically shaped by injectable GnRH agonists and conventional hormonal therapies.

AstraZeneca has an established presence through Zoladex, a goserelin-based GnRH agonist used in endometriosis management. AstraZeneca announced that the 3.6 mg monthly Zoladex implant would be discontinued in Australia for commercial reasons, demonstrating that product availability can be affected by portfolio and market economics even where a therapy has an established clinical role.

Bayer markets Visanne, a 2 mg dienogest tablet indicated for the treatment of endometriosis. Dienogest reduces endogenous estradiol production and suppresses ectopic endometrial tissue, positioning Bayer in the progestin-based treatment segment.

Debiopharm's Pamorelin, based on triptorelin, is a GnRH agonist used in gynecological conditions including endometriosis. The company's regional partnership model is relevant in markets where specialist access and local commercialization capabilities determine adoption.

Gedeon Richter has expanded the indication scope of Ryeqo, a relugolix, estradiol, and norethisterone acetate combination. The European Commission approved a Type II variation for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment in November 2023 ^{[9]Gedeon Richter Plc. - European Commission approval of Ryeqo for endometriosis, November 2, 2023 - gedeonrichter.com}.

Kissei Pharmaceutical developed linzagolix, marketed as Yselty in Europe through its licensing arrangements. Theramex received an additional European Commission indication for endometriosis for linzagolix in December 2024. Kissei also licensed Korean development and commercialization rights to JW Pharmaceutical in June 2024.

Pfizer commercializes Myfembree, a once-daily relugolix, estradiol, and norethindrone acetate therapy approved in the United States for moderate-to-severe endometriosis-associated pain in premenopausal women ^{[8]Pfizer Inc. - Myovant Sciences and Pfizer receive U.S. FDA approval of Myfembree, August 5, 2022 - pfizer.com}. The product's combination design reflects the competitive importance of managing both efficacy and estrogen-suppression-related tolerability.

Sanofi offers Danocrine, a danazol product indicated for endometriosis amenable to hormonal management. Danazol remains an established therapeutic option, although its androgenic profile differentiates it from newer GnRH-based and progestin-based approaches.

Teva Pharmaceutical participates through generic leuprolide formulations. Leuprolide injection is indicated for endometriosis treatment, and generic GnRH agonist availability remains important in price-sensitive treatment settings.

Zydus has developed extended-release dydrogesterone for endometriosis. A 2024 Phase III study reported significant reductions in endometriosis-associated pain scores with once-daily extended-release dydrogesterone 20 mg. Its India-focused development activity aligns with the need for locally relevant and potentially more accessible hormonal treatment options.

Recent Industry Developments

• June 2024: Kissei Pharmaceutical entered an agreement to out-license Korean development and commercialization rights for linzagolix to JW Pharmaceutical. The agreement provides for upfront, milestone, and royalty payments.
• August 2022: The U.S. Food and Drug Administration approved Myfembree for the management of moderate-to-severe pain associated with endometriosis in premenopausal women. The once-daily therapy combines relugolix, estradiol, and norethindrone acetate.
• February 2022: ObsEva entered a licensing agreement with Theramex for linzagolix commercialization outside the U.S., Canada, and Asia. The arrangement included potential payments of up to EUR 72.75 million, plus royalties.
• October 2021: Debiopharm and Dexa Medica launched triptorelin, marketed as Pamorelin, in Indonesia for women with gynecological disorders, particularly endometriosis.
• July 2021: The European Commission granted marketing authorization for Ryeqo for moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.